Division of Medical Services
Pharmacy Program

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851

ARKANSAS MEDICAID DUR BOARD
PHYSICIAN ADMINISTERED DRUGS (PAD) SUBCOMMITTEE

September 9, 2026 12:00 pm – 1:00 pm CST

VIRTUAL TEAMS MEETING LINK
Join the meeting now
Meeting ID: 233 781 903 264 22
Passcode: 3KF2cp7j

Dial in by phone
+1 501-244-3310,,979808470# United States, Little Rock
Phone conference ID: 979 808 470#

****TENTATIVE AGENDA IS SUBJECT TO CHANGE****

I. OUTSIDE SPEAKERS

Outside speakers with clinical or scientific credentials or patient experience pertinent to a product or topic that is posted on the upcoming PAD Subcommittee meeting agenda may request to speak on that product or topic. Public comments will not be permitted for topics not included on the agenda. Requests to speak at the PAD Subcommittee meeting must be made in writing to the DUR Chairperson (cinnamon.pearson@dhs.arkansas.gov) at least two (2) weeks before the PAD Subcommittee meeting date, and should include:

(1) The speaker's name, title, relevant credentials, and organization;
(2) Contact information for the speaker including address, telephone number, and email;
(3) The agenda item(s) which the speaker intends to address;
(4) Prepared comments which are not a reiteration of the FDA approved package insert; and
(5) Any educational materials for Board members in advance of the meeting.

This information shall be included in information sent to Subcommittee members two (2) weeks prior to the meeting. Presentations or public comments given at the PAD Subcommittee meeting are limited to a total of **three (3) minutes** per drug, which may be shared by multiple speakers. This time limit does not include responses to any questions raised by DUR Board Subcommittee members during the course of the meeting.

II. UNFINISHED BUSINESS

A. Vote on minutes from June 10, 2026 DUR PAD Subcommittee meeting
B. Implementation information from July 15, 2026 DUR Board meeting

7544-CD2 © 2025 Prime Therapeutics LLC

III. NEW BUSINESS

A. GENERAL MONOGRAPH UPDATES NOT REQUIRING REVIEW—none

B. UPDATE CURRENT MONOGRAPHS

1. DATROWAY (datopotamab deruxtecan-dlnk) for injection
2. KEYTRUDA/KEYTRUDA QLEX (pembrolizumab/ pembrolizumab and berahyaluronidase alfa-pmph) injection
3. OCREVUS (ocrelizumab) injection
4. TECENTRIQ (atezolizumab) injection
5. IMFINZI (atezolizumab) injection
6. TRODELVY (sacituzumab govitecan-hziy) for injection
7. TZIELD (teplizumab-mzwv) injection

C. NEW MONOGRAPHS

1. YARTEMLEA (narsoplimab-wuug) injection
2. ZIIHERA (zanidatamab-hrii) for injection,
3. KISUNLA (donanemab-azbt) injection
4. YEZTUGO (lenacapavir) injection
5. ZUSDURI (mitomycin) for intravesical solution
6. TEVIMBRA (tislelizumab-jsgr) injection
7. ADSTILADRIN (nadofaragene firadenovec-vncg) suspension, for intravesical use